Current Opinion in Hematology最新文献

筛选
英文 中文
Unraveling lipid metabolism for acute myeloid leukemia therapy. 揭示急性髓性白血病治疗中的脂质代谢。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-03-01 Epub Date: 2024-11-25 DOI: 10.1097/MOH.0000000000000853
Cristiana O'Brien, Courtney L Jones
{"title":"Unraveling lipid metabolism for acute myeloid leukemia therapy.","authors":"Cristiana O'Brien, Courtney L Jones","doi":"10.1097/MOH.0000000000000853","DOIUrl":"10.1097/MOH.0000000000000853","url":null,"abstract":"<p><strong>Purpose of review: </strong>The aim of this review is to highlight the importance of lipids' intricate and interwoven role in mediating diverse acute myeloid leukemia (AML) processes, as well as potentially novel lipid targeting strategies. This review will focus on new studies of lipid metabolism in human leukemia, particularly highlighting work in leukemic stem cells (LSCs), where lipids were assessed directly as a metabolite.</p><p><strong>Recent findings: </strong>Lipid metabolism is essential to support LSC function and AML survival through diverse mechanisms including supporting energy production, membrane composition, signaling pathways, and ferroptosis. Recent work has highlighted the role of lipid rewiring in metabolic plasticity which can underlie therapy response, the impact of cellular and genetic heterogeneity in AML on lipid metabolism, and the discovery of noncanonical roles of lipid related proteins in AML.</p><p><strong>Summary: </strong>Recent findings around lipid metabolism clearly demonstrates their importance to our understanding and therapeutic targeting of AML. We have only begun to unravel the regulation and utilization of lipids in this disease. Further, understanding the layered dynamics of lipid homeostasis could provide novel opportunities to target lipid metabolism in AML and LSCs with the potential of improving outcomes for patients with AML.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"77-86"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding. 骨髓性肿瘤中的胚系 DDX41 基因突变:目前的临床和分子认识。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-03-01 Epub Date: 2024-11-20 DOI: 10.1097/MOH.0000000000000854
Junichiro Kida, Timothy M Chlon
{"title":"Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding.","authors":"Junichiro Kida, Timothy M Chlon","doi":"10.1097/MOH.0000000000000854","DOIUrl":"10.1097/MOH.0000000000000854","url":null,"abstract":"<p><strong>Purpose of review: </strong>DDX41 mutations are the most common cause of germline predisposition to adult-onset myeloid neoplasms. The unique mutational landscape and clinical features indicate a distinct molecular pathogenesis, but the precise mechanism by which DDX41 mutations cause disease is poorly understood, owing to the multitude of DDX41 functions. In this review, we will update DDX41's known functions, present unique clinical features and treatment considerations, and summarize the current understanding of the molecular pathogenesis of the disease.</p><p><strong>Recent findings: </strong>Large cohort studies have revealed that germline DDX41 variants are heterozygous and predominantly loss-of-function. Acquired mutation of the contralateral DDX41 allele, typically R525H, is present in more than half of patients at disease onset, which occurs after age 50. DDX41 is essential for hematopoiesis and has versatile functions in RNA metabolism and innate immune sensing. Experimental models have suggested that innate immune activation downstream of defects in R-loop resolution and ribosome biogenesis plays a key role in the pathogenesis.</p><p><strong>Summary: </strong>While intensive investigations unveiled a strong genotype-phenotype relationship, the optimal therapeutic approach and long-term outcome are undefined. There is an urgent need to scrutinize the patients at single cell and multiomics level and to advance experimental animal and human models to fully elucidate the molecular pathogenesis.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"67-76"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Posttransplant cyclophosphamide: a universal graft versus host disease prophylaxis. 移植后环磷酰胺:一种通用的移植物抗宿主疾病预防疗法。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-03-01 Epub Date: 2024-11-21 DOI: 10.1097/MOH.0000000000000840
Andrea Bacigalupo
{"title":"Posttransplant cyclophosphamide: a universal graft versus host disease prophylaxis.","authors":"Andrea Bacigalupo","doi":"10.1097/MOH.0000000000000840","DOIUrl":"10.1097/MOH.0000000000000840","url":null,"abstract":"<p><strong>Purpose of review: </strong>The purpose of this review is to outline current graft versus host disease (GvHD) prophylaxis, in the era of posttransplant cyclophosphamide (PTCY), in patients with malignant and nonmalignant hematologic disorders. The original combination of PTCY with a calcineurin inhibitor (CNI) and mycophenolate (MMF), reported from the Johns Hopkins University in Baltimore, was designed for patients receiving a graft from a donor mismatched at one haplotype, so called haploidentical donor (HAPLO). In the past decade, PTCY has been widely used in HAPLO transplants worldwide, confirming the amazing efficacy of PTCY in preventing GvHD in mismatched grafts.</p><p><strong>Recent findings: </strong>More recently, PTCY is being tested also in grafts from human leukocyte antigen (HLA) identical related or unrelated donors. In the present review we will also answer several open questions, such as: PTCY and cardiac toxicity; PTCY dose; PTCY timing; PTCY and antithymocyte globulin (ATG); engraftment kinetics; infections; PTCY and leukemia relapse; PTCY and HLA identical grafts.</p><p><strong>Summary: </strong>PTCY is currently one of the most effective measures to prevent GvHD, and can be customized in different transplant platforms, together with other immunosuppressive agents. There is place for improvement, and several possible modifications of PTCY dose and schedule can be tested in prospective trials.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"104-108"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142683398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Platelets come together, in sweet harmony?! 血小板聚集在一起,在甜蜜的和谐中?
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-05 DOI: 10.1097/MOH.0000000000000844
Dianne E van der Wal
{"title":"Platelets come together, in sweet harmony?!","authors":"Dianne E van der Wal","doi":"10.1097/MOH.0000000000000844","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000844","url":null,"abstract":"","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":"32 1","pages":"1-3"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Platelets and circulating (tumor) cells: partners in promoting metastatic cancer. 血小板和循环(及肿瘤)细胞:促进癌症转移的伙伴。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-21 DOI: 10.1097/MOH.0000000000000852
Deepa Gautam, Emily M Clarke, Harvey G Roweth, Margaret R Smith, Elisabeth M Battinelli
{"title":"Platelets and circulating (tumor) cells: partners in promoting metastatic cancer.","authors":"Deepa Gautam, Emily M Clarke, Harvey G Roweth, Margaret R Smith, Elisabeth M Battinelli","doi":"10.1097/MOH.0000000000000852","DOIUrl":"10.1097/MOH.0000000000000852","url":null,"abstract":"<p><strong>Purpose of review: </strong>Despite being discovered decades ago, metastasis remains a formidable challenge in cancer treatment. During the intermediate phase of metastasis, tumor cells detach from primary tumor or metastatic sites and travel through the bloodstream and lymphatic system to distant tissues. These tumor cells in the circulation are known as circulating tumor cells (CTCs), and a higher number of CTCs has been linked to poor prognoses in various cancers. The blood is an inhospitable environment for any foreign cells, including CTCs, as they face numerous challenges, such as the shear stress within blood vessels and their interactions with blood and immune cells. However, the exact mechanisms by which CTCs survive the hostile conditions of the bloodstream remain enigmatic. Platelets have been studied for their interactions with tumor cells, promoting their survival, growth, and metastasis. This review explores the latest clinical methods for enumerating CTCs, recent findings on platelet-CTC crosstalk, and current research on antiplatelet therapy as a potential strategy to inhibit metastasis, offering new therapeutic insights.</p><p><strong>Recent findings: </strong>Laboratory and clinical data have provided insights into the role of platelets in promoting CTC survival, while clinical advancements in CTC enumeration offer improved prognostic tools.</p><p><strong>Summary: </strong>CTCs play a critical role in metastasis, and their interactions with platelets aid their survival in the hostile environment of the bloodstream. Understanding this crosstalk offers insights into potential therapeutic strategies, including antiplatelet therapy, to inhibit metastasis and improve cancer treatment outcomes.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"52-60"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of selective serotonin reuptake inhibitors on platelet functions: a literature review. 选择性血清素再摄取抑制剂对血小板功能的影响:文献综述。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-10-09 DOI: 10.1097/MOH.0000000000000847
Antoine Mokhtarian, Virginie Siguret, Georges Jourdi
{"title":"Effects of selective serotonin reuptake inhibitors on platelet functions: a literature review.","authors":"Antoine Mokhtarian, Virginie Siguret, Georges Jourdi","doi":"10.1097/MOH.0000000000000847","DOIUrl":"10.1097/MOH.0000000000000847","url":null,"abstract":"<p><strong>Purpose of review: </strong>Many epidemiological studies have evidenced an increased bleeding risk associated with selective serotonin reuptake inhibitors (SSRIs), yet the underlying mechanisms remain unclear. This review summarizes data on SSRIs' effects on platelet functions assessed with assays used in clinical practice and highlights the areas that deserve further investigation.</p><p><strong>Recent findings: </strong>Conflicting results of SSRI effects on platelet aggregation were observed irrespectively of the agonist used, the antidepressant drug or the study type. Alike, discrepant results were reported with flow-cytometry-based assays assessing either platelet surface glycoprotein levels, integrin activation, agonist-induced secretion of intraplatelet granule content or membrane anionic phospholipid exposure. Other tests may have detected a platelet function defect in SSRIs samples, however, results were largely inconsistent.</p><p><strong>Summary: </strong>Critical literature examination unveils very low certainty of evidence on potential SSRI effect on platelet functions. Findings are often inconsistent even when similar methods are used, most likely because of differences in study design, included patients (age, comorbid conditions), SSRIs' type and dose, uncontrolled confounding factors, and statistical analysis power. Further studies are needed to disentangle any intrinsic antiplatelet effect of SSRIs and the multiple confounding factors, mainly the depression control itself and the degree of platelet SERT inhibition.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"22-33"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introductions. 编辑介绍。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-05 DOI: 10.1097/MOH.0000000000000851
{"title":"Editorial introductions.","authors":"","doi":"10.1097/MOH.0000000000000851","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000851","url":null,"abstract":"","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":"32 1","pages":"v"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HCT in the widening spectrum of congenital immunodeficiencies. HCT 在不断扩大的先天性免疫缺陷中的应用。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-25 DOI: 10.1097/MOH.0000000000000849
Rafaella Muratori, Carmem Bonfim
{"title":"HCT in the widening spectrum of congenital immunodeficiencies.","authors":"Rafaella Muratori, Carmem Bonfim","doi":"10.1097/MOH.0000000000000849","DOIUrl":"10.1097/MOH.0000000000000849","url":null,"abstract":"<p><strong>Purpose of review: </strong>Hematopoietic stem cell transplantation (HSCT) and inborn errors of immunity (IEI) have been closely linked since transplantation was first used to cure severe combined immunodeficiency (SCID) in 1968. Since then, novel genes and diseases have been continually added to the ongoing list of IEI, and new data on indications and outcomes have emerged. We review recent data and progress in the field of hematopoietic cell transplantation (HCT) for IEI including new diseases and complications.</p><p><strong>Recent findings: </strong>Emerging data from haploidentical transplants, newborn screening results, and multicentric studies reveals promising outcomes for IEI. Immune dysregulation diseases deserve special attention regarding disease control and may require additional drugs pretransplant. Female carriers of X-linked Chronic granulomatous may present with a severe phenotype warranting the need for HCT. Insights from infectious complications and long-term comorbidities should help guide decisions to treat IEI patients.</p><p><strong>Summary: </strong>From classical indications to recently described diseases, HCT for immunodeficiencies is a rapidly growing field. Novel data regarding alternative donor transplants, results from large cohorts, and long-term complications provide valuable knowledge for clinical practice.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"61-66"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142734855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Platelet transfusion. 血小板输注。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-09-05 DOI: 10.1097/MOH.0000000000000843
Allison Mo, Erica Wood, Zoe McQuilten
{"title":"Platelet transfusion.","authors":"Allison Mo, Erica Wood, Zoe McQuilten","doi":"10.1097/MOH.0000000000000843","DOIUrl":"10.1097/MOH.0000000000000843","url":null,"abstract":"<p><strong>Purpose of review: </strong>Platelet transfusions, used as prophylaxis or treatment for bleeding, are potentially life-saving. In many countries, demand for platelet transfusion is rising. Platelets are a limited and costly resource, and it is vital that they are used appropriately. This study will explore the evidence behind platelet transfusions in different contexts, in particular recent and important research in this area.</p><p><strong>Recent findings: </strong>Recent randomized clinical trials demonstrate the efficacy of platelet transfusions in some contexts but potential detrimental effects in others. Platelet transfusions also carry risk of transfusion reactions, bacterial contamination and platelet transfusion refractoriness. Observational and clinical studies, which highlight approaches to mitigate these risks, will be discussed. There is growing interest in cold-stored or cryopreserved platelet units, which may improve platelet function and availability. Clinical trials also highlight the efficacy of other supportive measures such as tranexamic acid or thrombopoietin receptor agonists in patients with bleeding.</p><p><strong>Summary: </strong>Although platelet transfusions are beneficial in many patients, there remain many settings in which the optimal use of platelet transfusions is unclear, and some situations in which they may have detrimental effects. Future clinical trials are needed to determine optimal use of platelet transfusions in different patient populations.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"14-21"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Platelet-derived extracellular vesicles in cardiovascular disease and treatment - from maintaining homeostasis to targeted drug delivery. 心血管疾病和治疗中的血小板源性细胞外囊泡--从维持体内平衡到靶向给药。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-10-08 DOI: 10.1097/MOH.0000000000000845
Luisa Weiss, Hayley Macleod, Patricia B Maguire
{"title":"Platelet-derived extracellular vesicles in cardiovascular disease and treatment - from maintaining homeostasis to targeted drug delivery.","authors":"Luisa Weiss, Hayley Macleod, Patricia B Maguire","doi":"10.1097/MOH.0000000000000845","DOIUrl":"10.1097/MOH.0000000000000845","url":null,"abstract":"<p><strong>Purpose of review: </strong>Cardiovascular disease (CVD) remains a major global health burden. Rising incidences necessitate improved understanding of the pathophysiological processes underlying disease progression to foster the development of novel therapeutic strategies. Besides their well recognized role in CVD, platelet-derived extracellular vesicles (PEVs) mediate inter-organ cross talk and contribute to various inflammatory diseases.</p><p><strong>Recent findings: </strong>PEVs are readily accessible diagnostic biomarkers that mirror pathophysiological disease progression but also may confer cardioprotective properties. Monitoring the effects of modulation of PEV signatures through pharmacotherapies has also provided novel insights into treatment efficacy. Furthermore, exploiting their inherent ability to infiltrate thrombi, atherosclerotic plaques and solid tumours, PEVs as well as platelet-membrane coated nanoparticles are emerging as novel effective and targeted treatment options for CVD and cancer.</p><p><strong>Summary: </strong>Collectively, in-depth characterization of PEVs in various diseases ultimately enhances their use as diagnostic or prognostic biomarkers and potential therapeutic targets, making them clinically relevant candidates to positively impact patient outcomes.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"4-13"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信